Developing Novel, Targeted Immunotherapies for Cancer and Immune Disorders
The Immunotherapy stream highlights the most exciting tools, technologies and engineering strategies driving the development of cellular and non-cellular immunotherapies for cancer and immune disorders. Part One examines recent breakthroughs in T cell
biology, protein engineering and novel IO targets, plus new approaches for improving immunotherapy efficacy and safety. Part Two discusses the latest developments in cellular immunotherapy such as CAR Ts, TCRs, NKs, and TILs, including innovations
in allogenic cellular therapy, gene editing and targeting, all supported by in-depth case studies and clinical data.
Improving Immunotherapy Efficacy and Safety
CAR Ts, TCRs and TILs
Recommended Short Course:
SC1: CAR T Cell Therapy from A-Z
Instructor: Tara Arvedson, PhD, Executive Director, Oncology Research, Amgen, Inc.
Adrian Bot, PhD, Vice President and Global Head, Translational Medicine, Kite Pharma, a Gilead Company
David L. Porter, MD, Professor & Director Cell Therapy & Transplantation, Hematology & Oncology, University of Pennsylvania
Laszlo G. Radvanyi, PhD, President & Scientific Director, Ontario Institute for Cancer Research
Cameron J. Turtle, MBBS PhD, Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Centre